Lyka Labs Ltd.

BSE: LYKALABS500259ISIN INE933A01014

Healthcare
Pharmaceuticals

BSE listing

Share price

₹83.40-0.68 (-0.81%)

as of 18 Sep 2026

52W high: ₹104.80
52W low: ₹44.49
Off 52W high: -20.42%
1M return: +18.11%
3M return: +22.81%
6M return: +50.84%
1Y return: -16.60%
20D avg volume: 7,779
50 DMA: ₹71.51
200 DMA: ₹68.10

Key ratios Consolidated

Market cap: ₹301.51 Cr
Current price: ₹83.40
52W high / low: ₹104.80 / ₹44.49
Face value: ₹10.00
P/E: -32.13
P/B: —
EPS (TTM): ₹-2.60
Book value / share: —
ROE: —
ROCE: -7.00%
Operating margin: —
Net margin: —
Debt / equity: 0.53
Net debt: ₹47.00 Cr
Interest cover: -2.54
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 90.5 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	42.31	28.03	30.73	36.66	33.03	33.43	—
	0.42	0.61	1.16	1.09	0.63	0.82	—
	40.78	37.23	32.05	42.14	32.30	31.23	—
	11.20	7.43	7.33	8.97	8.05	9.68	—
	7.50	5.00	4.30	5.67	4.53	3.98	—
	11.49	12.91	9.49	10.40	9.05	9.61	—
	1.01	0.70	0.82	0.79	0.85	0.47	—
	2.01	2.04	2.15	2.15	2.11	1.42	—
	9.82	10.54	8.04	13.92	7.55	6.65	—
	1.95	-8.59	-0.16	-4.38	1.35	3.02	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	1.95	-8.59	-0.16	-4.38	1.35	3.02	—
	-0.10	-0.52	-0.01	-1.17	0.36	0.99	—
	2.05	-8.07	-0.15	-3.21	1.00	2.03	—
	0.57	-2.13	0.00	-0.94	0.25	0.49	—
Key metrics
	4.97	-5.85	2.81	-1.44	4.31	4.91	—
	11.70%	-20.90%	9.10%	-3.90%	13.00%	14.70%	—
	4.80%	-28.80%	-0.50%	-8.80%	3.00%	6.10%	—
	—	-6.50%	—	-2.90%	—	2.70%	—
	28.10%	-16.20%	—	—	—	—	—
	105.00%	-497.50%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	137.73	128.44	138.50	—
	3.28	3.50	2.23	—
	152.20	143.72	129.60	—
	34.93	31.77	37.07	—
	22.47	19.50	19.88	—
	44.29	41.85	34.63	—
	3.32	3.33	2.27	—
	8.35	8.46	6.77	—
	42.32	39.88	30.34	—
	-11.18	-11.78	11.12	—
	0.00	0.00	0.00	—
	-11.18	-11.78	11.12	—
	-1.80	-1.34	3.19	—
	-9.38	-10.44	7.93	—
	-2.50	-2.81	2.22	—
Key metrics
	0.49	0.01	20.16	—
	0.36%	0.00%	14.60%	—
	-6.81%	-8.10%	5.70%	—
	—	-7.00%	10.30%	—
	—	-7.30%	—	—
	—	-231.70%	—	—
	—	-5.89	-13.75	—
	—	-0.50	0.24	—
	—	0.53	0.37	—
	—	47.00	36.59	—
	—	90.5	107.0	—
Balance sheet
	—	174.54	176.21	—
	—	63.28	67.43	—
	—	1.36	1.34	—
	—	35.03	43.08	—
	—	13.63	12.47	—
	—	7.65	5.37	—
	—	80.40	76.90	—
	—	16.79	14.95	—
	—	53.90	46.63	—
	—	48.36	37.93	—
	—	25.37	18.72	—
	—	22.99	19.21	—
	—	90.83	103.58	—
Cash flow
	—	5.24	1.90	—
	—	-9.41	-11.80	—
	—	4.19	5.29	—
	—	11.13	15.65	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	42.31	28.03	30.73	32.97	29.18	30.52	—
	0.42	0.51	1.26	1.21	0.67	0.72	—
	40.73	35.43	31.71	38.98	28.67	28.97	—
	11.20	7.43	7.33	8.97	8.05	9.68	—
	7.50	5.00	4.30	3.25	2.25	2.10	—
	11.48	12.87	9.42	10.33	8.97	9.52	—
	1.01	0.87	0.82	0.79	0.85	0.52	—
	2.01	2.04	2.08	2.07	2.03	1.34	—
	9.79	8.61	7.84	13.34	6.36	6.40	—
	1.99	-6.89	0.28	-4.80	1.17	2.27	—
	0.00	-23.01	0.00	0.00	0.00	0.00	—
	1.99	-29.90	0.28	-4.80	1.17	2.27	—
	-0.11	-0.13	0.00	-1.17	0.36	0.97	—
	2.10	-29.77	0.28	-3.63	0.81	1.31	—
	0.58	-8.50	0.08	-1.02	0.22	0.36	—
Key metrics
	5.01	-26.99	3.18	-1.94	4.05	4.13	—
	11.80%	-96.30%	10.30%	-5.90%	13.90%	13.50%	—
	5.00%	-106.20%	0.90%	-11.00%	2.80%	4.30%	—
	—	-24.80%	—	-2.60%	—	1.70%	—
	45.00%	-8.20%	—	—	—	—	—
	159.30%	-2,372.50%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	134.04	120.91	134.70	—
	3.40	3.97	2.34	—
	146.85	135.10	125.57	—
	34.93	31.77	37.07	—
	20.05	14.80	17.52	—
	44.10	41.60	34.09	—
	3.49	3.33	2.30	—
	8.20	8.46	6.45	—
	39.58	36.22	29.50	—
	-9.42	-10.22	11.47	—
	-23.01	-23.01	0.00	—
	-32.43	-33.24	11.47	—
	-1.41	-0.95	3.25	—
	-31.02	-32.29	8.23	—
	-8.86	-9.18	2.28	—
Key metrics
	-20.74	-21.45	20.22	—
	-15.47%	-17.70%	15.00%	—
	-23.14%	-26.70%	6.10%	—
	—	-25.50%	8.60%	—
	—	-10.20%	—	—
	—	-492.30%	—	—
	—	-6.04	-12.43	—
	—	-0.16	0.40	—
	—	0.56	0.28	—
	—	47.17	36.61	—
	—	89.7	105.9	—
Balance sheet
	—	170.75	205.58	—
	—	60.45	66.12	—
	—	1.19	1.32	—
	—	32.91	40.45	—
	—	13.63	12.47	—
	—	7.12	4.70	—
	—	80.40	76.89	—
	—	16.79	13.83	—
	—	53.50	44.78	—
	—	48.36	37.93	—
	—	25.37	18.72	—
	—	22.99	19.21	—
	—	87.00	134.94	—
Cash flow
	—	5.09	3.27	—
	—	-9.42	-13.10	—
	—	4.19	5.26	—
	—	11.13	15.70	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 58.46%

Holder	Type	Holding	Previous	Change
IPCA LABORATORIES LIMITED	Promoter	40.45%	—	—
KUNAL NARENDRA GANDHI	Promoter	10.03%	—	—
NEHAL NARENDRA GANDHI	Promoter	3.60%	—	—
ENAI TRADING AND INVESTMENT PVT. LTD	Promoter Group	3.04%	—	—
THERMO CAPITAL PRIVATE LIMITED	Public	1.94%	—	—
DALAL & BROACHA STOCK BROKING PVT.LTD.	Public	1.31%	—	—
PRANAY GODHA	Promoter	0.83%	—	—
ALISHA KUNAL GANDHI	Promoter Group	0.14%	—	—
SWETA SHAH	Promoter Group	0.11%	—	—
USHMA RONAK SHAH	Promoter Group	0.09%	—	—
LYKA GENERICS LIMITED	Promoter Group	0.06%	—	—
PREMCHAND GODHA	Promoter	0.03%	—	—
USHA GODHA	Promoter	0.03%	—	—
NEETU GODHA	Promoter	0.03%	—	—
BHAWNA GODHA	Promoter	0.02%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

As per the letter attached12 Aug 2026 · Company Update / Newspaper Publication
As per the letter attached11 Aug 2026 · AGM/EGM / AGM
As per the letter attached11 Aug 2026 · Company Update / General
As per the letter attached10 Aug 2026 · AGM/EGM / AGM
As per the letter atatched10 Aug 2026 · Company Update / General
As per the letter attached10 Aug 2026 · Result / Financial Results
As per the letter attached10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve As per the letter attached24 Jul 2026 · Board Meeting / Board Meeting
As per the letter attached20 Jul 2026 · Company Update / Newspaper Publication
As per the letter attached17 Jul 2026 · AGM/EGM / AGM
As per the letter attached17 Jul 2026 · Company Update / General
As per the letter attached17 Jul 2026 · Others / Reg. 34 (1) Annual Report
As per the letter attached17 Jul 2026 · AGM/EGM / AGM
As per the letter attached10 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per the letter attached8 Jul 2026 · Company Update / Newspaper Publication
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kunal Gandhi & PACs30 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
As per the letter attached30 Jun 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kunal Gandhi & Others29 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
As per letter attached26 Jun 2026 · Company Update / General
As per letter attached24 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
As per the letter attached17 Jun 2026 · Company Update / General
As per the letter attached12 Jun 2026 · Company Update / Allotment of Equity Shares
Clarification on Price Movement11 Jun 2026 · Company Update / General
The Exchange has sought clarification from Lyka Labs Ltd on June 11, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....11 Jun 2026 · Company Update / Clarification
As per attachment4 Jun 2026 · Company Update / General
As per regulation 47 of the SEBI (LODR) Regulations, 2015 the extract of Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31.03.2026 were published ....27 May 2026 · Company Update / Newspaper Publication
Annual Secretarial Compliance Report for the year ended 31.03.202626 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
As per the letter attached25 May 2026 · Result / Financial Results
As per the letter attached25 May 2026 · Board Meeting / Outcome of Board Meeting
Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve As per letter attached12 May 2026 · Board Meeting / Board Meeting
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....30 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Pursuant to Regulation 30 of the SEBI (LODR) Regulations 2015 we wish to inform you that India Rating & Research Pvt. Ltd. has assigned/affirmed the rating of the bank facilities availed ....30 Apr 2026 · Company Update / Credit Rating
As per the letter attached9 Apr 2026 · Company Update / General
As per the letter attached9 Apr 2026 · Company Update / General
The Exchange has sought clarification from Lyka Labs Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....8 Apr 2026 · Company Update / Clarification
As per the letter attached7 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per the letter attached31 Mar 2026 · Board Meeting / Outcome of Board Meeting
Closure of Trading Window27 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/03/2026 ,inter alia, to consider and approve As per the letter attached23 Mar 2026 · Board Meeting / Board Meeting
Update on the Scheme of Merger- Approved by NCLT Bench17 Mar 2026 · Company Update / General

Board meetings

10 Aug 2026 Board Meeting - Financial Results